Novo pairs up with Weight Watchers after dumping Hims

Novo Nordisk announced Thursday that it’s pairing up with Weight Watchers to distribute its blockbuster weight-loss shot, which comes days after a similar partnership with Hims & Hers imploded.

Novo has been looking for ways to spark sales growth for its diabetes and weight-loss drugs, Ozempic and Wegovy, as it faces increased competition and lackluster trial results for its potential successor treatment. The deal could also be a lifeline for Weight Watchers, which just filed for bankruptcy last month.

Novo and Eli Lilly have partnered with telehealth companies to sell their weight-loss shots for a cheaper price than what they charge insured patients. Novo has these partnerships with Ro, LifeMD, and now Weight Watchers.

Novo also partnered with Hims, but it abruptly called that off on Monday. The drugmaker accused the telehealth platform of illegally mass compounding its patented drugs.